MP758: East Regional Potato Trials 2006: Summary of NE1014 Regional Project Field Testing of New Potato Clones

The objectives of this regional potato trial are (1) to develop pest-resistant, early-maturing, long-dormant potato varieties that will process from cold storage; (2) to evaluate new and specialty variet­ies developed in the Northeast; (3) to determine climatic effects on performance to develop pre­dictive models for potato improvement; and (4) determine heritability/linkage relationships and improve the genetic base of tetraploid cultivated varieties. The results presented in this report reflect a portion of the activity directed toward objectives 1, 2 and 3.https://digitalcommons.library.umaine.edu/aes_miscpubs/1017/thumbnail.jp

MP760: East Regional Potato Trials 2007: Summary of NE1014 Regional Project Field Testing of New Potato Clones

The objectives of this regional potato trial are (1) to develop pest-resistant, early-maturing, long-dormant potato varieties that will process from cold storage; (2) to evaluate new and specialty variet­ies developed in the Northeast; (3) to determine climatic effects on performance to develop pre­dictive models for potato improvement; and (4) determine heritability/linkage relationships and improve the genetic base of tetraploid cultivated varieties. The results presented in this report reflect a portion of the activity directed toward objectives 1, 2 and 3.https://digitalcommons.library.umaine.edu/aes_miscpubs/1016/thumbnail.jp

MP757: Eastern Regional Potato Trials 2005: Summary of NE1014 Regional Project Field Testing of New Potato Clones

The objectives of this regional potato trial are (1) to develop pest-resistant, early-maturing, long-dormant potato varieties that will process from cold storage; (2) to evaluate new and specialty variet­ies developed in the Northeast; (3) to determine climatic effects on performance to develop pre­dictive models for potato improvement; and (4) determine heritability/linkage relationships and improve the genetic base of tetraploid cultivated varieties. The results presented in this report reflect a portion of the activity directed toward objectives 1, 2 and 3.https://digitalcommons.library.umaine.edu/aes_miscpubs/1018/thumbnail.jp

Safety, tolerability and efficacy of a rapid dose escalation of quetiapine in bipolar I mania: the FATIMA study

Objective The FATIMA study (FAst TItration of quetiapine fumarate in bipolar I MAnia) evaluated the safety, tolerability and efficacy of a rapid dose escalation of quetiapine in acutely ill bipolar I patients experiencing a manic episode. Methods In an open-label, phase II pilot study, 29 patients aged 18 years or older, hospitalised with a bipolar I manic episode, received quetiapine twice daily for 21 days. Quetiapine was administered at 200, 400, 600, then 800 mg/day on the first 4 days, with flexible dosing (400-800 mg/day) subsequently. The primary endpoint was the proportion of patient dropouts because of adverse drug reactions during the first 7 days. Secondary safety assessments included incidences of adverse drug reactions and significant changes in vital signs. Efficacy assessments included Young Mania Rating Scale (YMRS) and Clinical Global Impressions Severity of Illness (CGI-S) score changes from day 1 to day 21. Results Twenty patients (69%) completed the study. No patients withdrew as a result of drug-related adverse events (AEs) during the first 7 days. Twenty-three patients reported 58 adverse events, and most of the adverse events were mild or moderate. No clinically relevant abnormalities in vital signs were reported. Mean YMRS and CGI-S scores decreased significantly from baseline to day 21 (p < 0.001). Response and remission rates were 78 and 70%, respectively, at the end of the study. Conclusion Rapid dose escalation of quetiapine to 800 mg/day over 4 days was well tolerated and effective in reducing symptoms within 5 days in acutely ill bipolar I patients with a manic episode